NuPotential is leveraging its proprietary NP-Reprog cell reprogramming platform and NP-Epidrugs to develop in vitro models of disease, or "NP-Disease in a Dish,"
for preclinical drug discovery, toxicity testing, and disease research.
Existing disease models have significant limitations in disease
mimicry, survivability, and availability. NP-Disease in a Dish models will be a novel, cost-effective tool to recapture disease in vitro,
providing needed improvements to current drug discovery and development
platforms found within the pharmaceutical industry.
NP-Disease in a Dish
models are prepared from minimally invasive tissue samples of patients
that are suffering from various chronic disease indications.
Using the novel and proprietary small molecule-focused NP-Reprog platform,
tissue samples (skin, for instance) are reprogrammed to a pluripotent
state and can then be differentiated into desired tissue lineages for
numerous research and development applications. These cells, in
addition to their development conduits (NP-iPS -pluripotent
cell lines) will afford NuPotential and its prospective partners robust
and flexible capabilities in; 1) disease R&D; 2) drug discovery and
development; and 3) drug repositioning.
NP-Disease in a Dish highlights include:
NP-Disease in a Dish
models will first be generated from sufferers of metabolic
disease-related indications (type 2 diabetes, obesity, heart disease).
In vitro models of liver and neuronal associated chronic diseases are also in development. NuPotential will license NP-Disease ina Dish
and complementary technologies for a potential partner's internal
development, and, dependent on our partner's needs, will produce
partner-specific NP-Disease in a Dish cell lines for thier use.
- Generated using the novel and proprietary NP-Reprog cell reprogramming platform:
- Small molecule-based reprogramming platform with
- Cell lines developed withNP-Reprog have
Small molecule-based reprogramming
does not alter genomic-related
to a large and diverse patient population to aid in the development of
substantial libraries of disease models with patient-specific disease
phenotypes of metabolic-related diseases.
- PIER and NP-Reprog driven technology.
- Strong IP support.
Louisiana Emerging Technology Center, 340, E. Parker Blvd., Baton Rouge, LA 70803 • 225/615-8955
Copyright© 2012 NuPotential, Inc. All rights reserved.